[Ketamine in chronic pain].
Intérêt de la kétamine dans le traitement des douleurs chroniques.
adverse effects
chronic pain
douleur chronique
effets indésirables
efficacité
efficacy
ketamine
kétamine
Journal
Biologie aujourd'hui
ISSN: 2105-0686
Titre abrégé: Biol Aujourdhui
Pays: France
ID NLM: 101544020
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
02
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Ketamine is now frequently used in the management of chronic pain refractory to conventional treatments. However, its efficacy and adverse effects appear variable in the literature in line with heterogeneous methodologies and modes of administration, leading to controversy regarding the actual interest of ketamine for chronic pain treatment. A need for clinical trials on larger cohorts of well selected patients but also real-life studies to more accurately quantify its efficacy, refine its prescription dosages and better understand its long-term adverse effects is highlighted in the literature. Progress in this direction has been achieved in recent years with improved recommendations for use, taking into account different trajectories of analgesia with ketamine, depending on the etiology of the pain, and the psycho-affective profile of patients. A holistic approach is clearly needed with consideration of pain and depression comorbidities to optimize pain management. Intérêt de la kétamine dans le traitement des douleurs chroniques. La kétamine est aujourd’hui fréquemment utilisée dans la prise en charge de la douleur chronique réfractaire aux traitements classiques. Selon les études, l’efficacité et les effets indésirables de la kétamine apparaissent variables, en lien avec des méthodologies et des modes d’administration hétérogènes, conduisant à des controverses sur son utilisation en clinique. Un besoin d’essais sur des cohortes plus nombreuses de patients mieux sélectionnés mais aussi d’études en « vraie vie » pour mieux quantifier son efficacité, raffiner les posologies de prescription et mieux comprendre ses effets indésirables à long terme, est régulièrement souligné dans la littérature. Toutefois, au cours des dernières années, plusieurs travaux ont permis d’avancer sur les recommandations d’utilisation. Ils soulignent en particulier la nécessité de prendre en compte à la fois les trajectoires diverses d’antalgie avec la kétamine, selon l’étiologie de la douleur, et les comorbidités, en particulier la dépression, afin d’optimiser la prise en charge des patients douloureux.
Autres résumés
Type: Publisher
(fre)
Intérêt de la kétamine dans le traitement des douleurs chroniques.
Identifiants
pubmed: 38018941
doi: 10.1051/jbio/2023019
pii: jbio230019
doi:
Substances chimiques
Ketamine
690G0D6V8H
Analgesics
0
Types de publication
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
145-149Informations de copyright
© Société de Biologie, 2023.
Références
ANSM. (2010). Douleur rebelle en situation palliative avancée chez l’adulte – Recommandations de bonne pratique. http://ansm.sante.fr/.
ANSM. (2017). Kétamine : risque d’atteintes hépatiques graves lors d’utilisations prolongées et/ou à doses élevées – Point d’Information. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Ketamine-risque-d-atteintes-hepatiques-graves-lors-d-utilisations-prolongees-et-ou-a-doses-elevees-Point-d-Information.
Chan, E.O.T., Chan, V.W.S., Tang, T.S.T., Cheung, V., Wong, M.C.S., Yee, C.H., Ng, C.F., Teoh, J.Y.C. (2022). Systematic review and meta-analysis of ketamine-associated uropathy. Hong Kong Med J, 28, 466-474.
Chizh, B.A. (2007). Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol, 21, 259-271.
Cohen, S.P., Bhatia, A., Buvanendran, A., Schwenk, E.S., Wasan, A.D., Hurley, R.W., Viscusi, E.R., Narouze, S., Davis, F.N., Ritchie, E.C., Lubenow, T.R., Hooten, W.M. (2018). Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med, 43, 456-466.
Cook-Sather, D., Adamson, P.C., Li, J., Hakonarson, H. (2016). CYP2B6*6 or not CYP2B6*6-that remains a question for precision medicine and ketamine! Anesthesiology, 125, 1085-1087.
Corriger, A., Pickering, G. (2019). Ketamine and depression: a narrative review. Drug Des Devl Ther, 13, 3051-3067.
Corriger, A., Voute, M., Lambert, C. Pereira, B., Pickering, G., OKAPI Consortium. (2022). Ketamine for refractory chronic pain: a 1-year follow-up study. Pain, 163, 690-701.
Corssen, G., Domino, E.F. (1966). Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg, 45, 29-40.
Curran, H.V., Monaghan, L. (2001). In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction, 96, 749-760.
Grégoire, M.C., MacLellan, D.L., Finley, G.A. (2008). A pediatric case of ketamine-associated cystitis (letter-to-the-Editor RE: Shahani, R., Streutker, C., Dickson, B., et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69, 810-812, 2007). Urology, 71, 1232-1233.
Hashimoto, K. (2012). A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin Psychopharmacol Neurosci, 10, 59-60.
Heinzel, A., Steinke, R., Poeppel, T.D., Grosser, O., Bogerts, B., Otto, H., Northoff, G. (2008). S-ketamine and GABA-A-receptor interaction in humans: an exploratory study with I-123-iomazenil SPECT. Hum Psychopharmacol, 23, 549-554.
Hirota, K., Okawa, H., Appadu, B.L., Grandy, D.K., Devi, L.A., Lambert, D.G. (1999). Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology, 90, 174-182.
Huang, M.C., Chen, C.H., Liu, T.H., Chung, A.N., Liu, Y.L., Quednow, B.B., Bavato, F. (2023). Comorbidity of ketamine dependence with major depressive disorder increases the vulnerability to neuroaxonal pathology. J Psychiatr Res, 158, 360-364.
Jonkman, K., Dahan, A., van de Donk, T., Aarts, L., Niesters, M., van Velzen, M. (2017). Ketamine for pain. F1000Res 6. pii: F1000 Faculty Rev-1711.
Lodge, D., Anis, N.A., Burton, N.R. (1982). Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett, 29, 281-286.
Loo, C. (2018). Can we confidently use ketamine as a clinical treatment for depression? Lancet Psychiatry 5, 11-12.
Maher, D.P., Chen, L., Mao, J. (2017). Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg, 124, 661-674.
Meshkat, S., Rodrigues, N.B., Di Vincenzo, J.D. (2021). Pharmacogenomics of ketamine: a systematic review. J Psychiatr Res, 145, 27-34.
Mion, G., Villevieille, T. (2013). Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther, 19, 370-380.
Moisset, X., Bouhassira, D., Avez Couturier, J., Alchaar, H., Conradi, S., Delmotte, M.H., Lanteri-Minet, M., Lefaucheur, J.P., Mick, G., Piano, V., Pickering, G., Piquet, E., Regis, C., Salvat, E., Attal, N. (2020). Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Revue neurologique, 176, 325-352.
Niesters, M., Martini, C., Dahan, A. (2014). Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol, 77, 357-367.
Orhurhu, V.J., Roberts, J.S., Ly, N., Cohen, S.P., Ketamine in acute and chronic pain management, in: StatPearls [Internet], StatPearls Publishing, Treasure Island (FL), 2022. PMID: 30969646.
Peltoniemi, M.A., Hagelberg, N.M., Olkkola, K.T., Saari, T.I. (2016). Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet, 55, 1059-1077.
Peskin, E., Gudin, J., Schatman, M.E. (2023). Increased demand for ketamine infusions and associated complexities. J Pain Res, 16, 295-299.
Pfenninger, E.G., Durieux, M.E., Himmelseher, S. (2002). Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology, 96, 357-366.
Pickering, G., Morel, V., Micallef, J. (2018). Ketamine and chronic pain: a narrative review of its efficacy and its adverse events. Thérapie, 73, 529-539.
Pickering, G., Pereira, B., Morel, V., Corriger, A., Giron, F., Marcaillou, F., Bidar-Beauvallot, A., Chandeze, E., Lambert, C., Bernard, L., Delage, N. (2020). Ketamine and magnesium for refractory neuropathic pain: a randomized, double-blind, crossover trial. Anesthesiology, 133, 154-164.
Sears, B.E. (1975). Experience with ketamine anesthesia. J Natl Med Assoc, 67, 32-35.
Seeman, P., Ko, F, Tallerico, T. (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry, 10, 877-883.
SFETD. (2019). https://www.sfetd-douleur.org/guides-des-bonnes-pratiques/Novembre2019.
Shahani, R., Stewart, R.J. (2008). Reply to letter-to-the-Editor [Re: Shahani, R., Streutker, C., Dickson, B. (2007). Ketamine-associated ulcerative cystitis: a new clinical entity. Urology, 69, 810-812] Urology, 71, 987.
Short, B., Fong, J., Galvez, V., Shelker, W., Loo, K. (2018). Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry, 5, 65-78.
Sinner, B., Graf, B.M. (2008). Ketamine. Handb Exp Pharmacol, 182, 313-333.
Suzuki, M., Edmonds, H.L. Jr, Tsueda, K., Malkani, A.L., Roberts, C.S. (1998). Effect of ketamine on bispectral index and levels of sedation. J Clin Monit Comput, 14, 373.
Turkish, A., Luo, J.J., Lefkowitch, J.H. (2013). Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology, 58, 825-827.
Voute, M., Riant, T., Amodéo, J.M., André, G., Barmaki, M., Collard, O., Colomb, C., Créac’h, C., Deleens, R., Delorme, C., de Montgazon, G., Dixneuf, V., Dy, L., Gaillard, J., Gov, C., Kieffer, X., Lanteri-Minet, M., Le Borgne, J.M., Le Caër, F., Maamar, F., Maindet, C., Marcaillou, F., Plantevin, F., Pluchon, Y.M., Rioult, B., Rostaing, S., Salvat, E., Sep Hieng, V., Sorel, M., Vergne-Salle, P., Morel, V., de Chazeron, I., Pickering, G. (2022). Ketamine in chronic pain: a Delphi survey. Eur J Pain, 26, 873-887.
Yanagihara, Y., Ohtani, M., Kariya, S., Uchino, K., Hiraishi, T., Ashizawa, N. (2003). Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos, 24, 37-43.
Zukin, S.R., Fitz-Syage, M.L., Nichtenhauser, R., Zukin, R.S. (1983). Specific binding of [